Reference
1. Costello SE, Gales AC, Morfin-Otero R, et al. Mechanisms of
resistance, clonal expansion, and increasing prevalence of acinetobacter
baumannii strains displaying elevated tigecycline MIC values in Latin
America. Microb Drug Resist. 2016 ;22(4):1-6.
2. Liang W, Yuan-Run Z, Min Y. Clinical presentations and outcomes of
post-operative central nervous system infection caused by
multi-drug–resistant/extensively drug-resistant Acinetobacter
baumannii: a retrospective study. Surg Infect (Larchmt). 2019;20(6):1-5.
3. Moon C, Kwak YG, Kim BN, et al. Implications of post neurosurgical
meningitis caused by carbapenem-resistant Acinetobacter baumanni. J
Infect Chemother. 2013;19(5):916-919.
4. Talaga K, Krzyściak P, Bulanda M. Susceptibility to tigecycline of
Acinetobacter baumannii strains isolated from intensive care unit
patients. Anaesthesiol Intensive Ther. 2016;48(3):166-170.
5. Zhou Y, Chen X, Xu P, et al. Clinical experience with tigecycline
in the treatment of hospital-acquired pneumonia caused by multidrug
resistant Acinetobacter baumannii. BMC Pharmacol Toxicol.
2019;20(1):1-8.
6. Pallotto C, Fiorio M, D’Avolio A, et al. Cerebrospinal fluid
penetration of tigecycline. Scand J Infect Dis. 2014;46(1):69-72.
7. Wu X, Zhu Y, Chen Q, et al. Tigecycline therapy for nosocomial
pneumonia due to carbapenem-resistant gram-negative bacteria in
critically ill patients who received in appropriate initial antibiotic
treatment: a retrospective case study. Biomed Res Int. 2016;4:1-6.
8. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid
concentrations of tigecycline after a single 100 mg dose. J Antimicrob
Chemother. 2006;58(6):1221-1229.
9. Mendes B, Marques C, Carvalho I, et al. Influence of glioma cells on
a new co-culture in vitro blood-brain barrier model for characterization
and validation of permeability. Int J Pharm. 2015 25;490:94-101.
10. Mei S, Luo X, Li X, et al. Development and validation of a LC-MS/MS
method for the determination of tigecyclinein human plasma and
cerebrospinal fluid and its application to a pharmacokinetic study.
Biomed Chromatogr. 2016;30(12):1992-2002.
11. Shao R, Li X, Hu Y, et al. Determination of tigecycline in human
plasma by LC-MS/MS and its application to population pharmacokinetics
study in Chinese Patients with hospital-acquired pneumonia. Biomed
Chromatogr. 2018;32(2):e4045.
12. Pardridge WM. Blood-brain barrier genomics and the use of endogenous
transporters to cause drug penetration into the brain, Curr Opin Drug
Discov Devel. 2003;6(5):663-691.
13. Abbott NJ, Friedman A. Overview and introduction: The blood–brain
barrier in health and disease. Epilepsia. 2012; 53 Suppl 6(06):1-9.
14. Lee CH, Tang YF, Su LH, Chien CC, Liu JW, Antimicrobial effects of
varied combinationsof meropenem, sulbactam, and colistin on a
multidrug-resistant Acinetobacter baumannii isolate that caused
meningitis and bacteremia. Microb Drug Resist. 2008;14(3):233-237.
15. Morfin-Otero R, Dowzicky MJ, Changes in MIC. Within a global
collection of Acinetobacter baumannii collected as part of the
tigecycline evaluationand surveillance trial, 2004 to 2009. Clin
Ther;34(1):101-112.
16. Fang YQ, Zhan RC, Jia W, et al. A case report of intraventricular
tigecycline therapy for intracranial infection with extremely drug
resistant Acinetobacter baumannii. Medicine
(Baltimore). 2017;96(31):1-4.
17. Chen J, Orsini J, Killu C. Poor central nervous system penetration
of tigecycline in a patient with sepsis and ventriculitis caused by
multidrug-resistant Klebsiella pneumonia. J Pharm Technol.
2007;23:344-348.
18. Leslie R, Kimberly L, David P N, et al. Cerebral spinal fluid
penetration of tigecycline in a patient with Acinetobacter baumannii
cerebritis. Ann Pharmacother. 2010;44:582-586.
19. Guo S, Li F, Wang B, et al. Analysis of tizoxanide, active
metabolite of nitazoxanide, in rat brain tissue and plasma by
UHPLC–MS/MS. Biomed Chromatogr. 2020;34(2):e1-7.
20. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J
Antimicrob Chemother. 2008;62 Suppl 1:i11-i16.